Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib as an adjunct to radioiodine in radioiodine-refractory non-medullary thyroid carcinoma
NL-OMON31009Phase 2Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sorafenib in thyroid cancer, sponsored by Amsterdam University Medical Center. Planned start Sep 2007; status: not yet recruiting.
02
Drugs
sorafenib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NL-OMON31009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31009.